Conclusions
VIV-TAVR is safe and effective in the early period. In surgical valves
with a true-ID≤21mm inferior hemodynamic and survival outcomes must be
expected. Nonetheless, also patients with larger true-ID’s showed
steadily increasing transvalvular gradients. This raises concern about
durability.